关键词: 肾移植, 供体来源性感染, 头孢哌酮舒巴坦钠, 鲍曼不动杆菌, 白色念珠菌

Abstract: Objective To summarize the experience of donor selection and receptor therapy in the face of potential donor infection, which improves the quality of the use of donor organs, reduces the risk of postoperative infection and the loss of transplant kidney and recipient mortality. Methods This study used a retrospective analysis of 59 kidneys from 31 donors and corresponding recipients from April 2017 to March 2018. Results The pathogenic culture of only 10 donors in 31 donors were totally negative, accounting for only 32%. Two receptors whose donor's blood culture was positive for Acinetobacter baumannii were treated with cefoperazone sulbactam sodium and tigecycline; two receptors whose donor's phlegm culture was positive for Acinetobacter baumannii were treated with cefoperazone sulbactam sodium; for the donor whose phlegm culture was positive for Candida albicans, the responding recipient whose urine culture was positive for the same pathogenic bacteria was treated with fluconazole; none of the above recipients experienced serious adverse events caused by donor-derived infections after targeted anti-infective treatment. Conclusion Although it is quite common for the donor to have an infection before the organ is acquired, we could improve prognosis of the patients and reduce the serious adverse events caused by donor-derived infections through a package of measures, such as target and preventive application of appropriate and prophylactic antibiotics to the corresponding donors, closely detecting changes in infection indicators, and adjusting medications timely.

Key words: kidney transplantation, donor-derived infection, cefoperazone sulbactam sodium, acinetobacter baumannii, candida albicans